Neoadjuvant chemotherapy for upper tract urothelial carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Do Kyung | - |
dc.contributor.author | Cho, Kang Su | - |
dc.date.accessioned | 2021-09-10T06:48:00Z | - |
dc.date.available | 2021-09-10T06:48:00Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 2218-676X | - |
dc.identifier.issn | 2219-6803 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19432 | - |
dc.description.abstract | Upper tract urothelial carcinoma (UTUC) is a very uncommon disease that occupies for <5% of all urothelial cancers. Radical nephroureterectomy (RNU) remains the standard- of-care for UTUC; however, when patients with locally advanced UTUC are treated with RNU only, the recurrence rate is high. Therefore, perioperative chemotherapy has been proposed given the high systemic recurrence rate. Moreover, there is growing evidence that neoadjuvant chemotherapy (NAC) plays an important role in the treatment of UTUC. Several studies and meta-analyses have reported the beneficial effect of NAC on survival outcomes and pathologic downstaging of patients with UTUC. However, the recommendation of NAC for UTUC is primarily based on level 1 evidence that demonstrated a beneficial effect on survival outcomes in patients with bladder cancer. The chemotherapy regimen for patients with UTUC is also based on that used for patients with bladder cancer. Nevertheless, the use of NAC for UTUC has some limitations, including the possibility of overtreatment. Therefore, selection criteria for NAC are needed, as are further trials to identify the most suitable patients and validate its use in daily clinical practice. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AME Publishing Company | - |
dc.title | Neoadjuvant chemotherapy for upper tract urothelial carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 중국 | - |
dc.identifier.doi | 10.21037/tcr.2020.03.08 | - |
dc.identifier.scopusid | 2-s2.0-85096131197 | - |
dc.identifier.wosid | 000585306900072 | - |
dc.identifier.bibliographicCitation | Translational Cancer Research, v.9, no.10, pp 6576 - 6582 | - |
dc.citation.title | Translational Cancer Research | - |
dc.citation.volume | 9 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 6576 | - |
dc.citation.endPage | 6582 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | UPPER URINARY-TRACT | - |
dc.subject.keywordPlus | INVASIVE BLADDER-CANCER | - |
dc.subject.keywordPlus | CHRONIC KIDNEY-DISEASE | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PERIOPERATIVE CHEMOTHERAPY | - |
dc.subject.keywordPlus | PD-L1 EXPRESSION | - |
dc.subject.keywordPlus | CELL-CARCINOMA | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | NEPHROURETERECTOMY | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Neoadjuvant | - |
dc.subject.keywordAuthor | Nephroureterectomy | - |
dc.subject.keywordAuthor | Upper tract urothelial carcinoma (UTUC) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.